<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7527651\results\search\testTrace\results.xml">
  <result pre="their interactions with TB are discussed with implications for diagnosis," exact="treatment" post="and prevention of airborne infections (infection control, viral containment"/>
  <result pre="and COVID-19) and their interactions with TB at a diagnostic," exact="treatment" post="and public health level. The document is the fruit"/>
  <result pre="no formal recommendations are provided. The available information on prevention," exact="diagnosis" post="and treatment of TB and pulmonary viral diseases was"/>
  <result pre="recommendations are provided. The available information on prevention, diagnosis and" exact="treatment" post="of TB and pulmonary viral diseases was selected by"/>
  <result pre="The clinical spectrum can encompass asymptomatic infection, upper respiratory tract" exact="infection" post="and lower respiratory tract infection that can result in"/>
  <result pre="asymptomatic infection, upper respiratory tract infection and lower respiratory tract" exact="infection" post="that can result in pneumonia or acute respiratory distress"/>
  <result pre="result in pneumonia or acute respiratory distress [11], and systemic" exact="infection" post="[12]. The severity of viral respiratory illness varies widely"/>
  <result pre="smaller role of CD8+ T-cells in protection against M. tuberculosis" exact="infection" post="[37], and an even smaller contribution of B-cells and"/>
  <result pre="shown a decrease of this CD8 T-cell response during anti-TB" exact="treatment" post="[39, 40]. It has been shown that the cells"/>
  <result pre="influenza patients admitted to intensive care units (ICUs). Its global" exact="prevalence" post="varies between 0.1% and 10% according to historical surveys,"/>
  <result pre="for virus-induced immunopathological events in causing fatal pneumonia following coronavirus" exact="infection" post="[69]. High initial viral titres in the airways, age"/>
  <result pre="imaging by chest radiography, ultrasound and CT are important for" exact="diagnosis" post="and management. Main CT abnormalities include ground-glass opacity and"/>
  <result pre="guiding the aetiological evaluation of lung infections [102]. Pulmonary TB" exact="infection" post="and reactivation are more likely with a CD4 count"/>
  <result pre="(e.g. asthma and COPD). As a large proportion of post-TB" exact="treatment" post="patients have long-term functional impairment, mainly COPD, which can"/>
  <result pre="pulmonary sequelae may be predisposed and more susceptible to influenza" exact="infection" post="and its complications, including mortality [106]. Furthermore, the temporary"/>
  <result pre="patients in South Africa [107]. TB patients have a similar" exact="prevalence" post="of viral and bacterial co-infection as their household contacts,"/>
  <result pre="the development of active TB among patients with latent TB" exact="infection" post="(LTBI) [111]; however, the occurrence of TB may occur"/>
  <result pre="This elevated risk is behind the WHO recommendation of TB" exact="screening" post="and/or preventive treatment for all PLWHA [119, 120]. New"/>
  <result pre="is behind the WHO recommendation of TB screening and/or preventive" exact="treatment" post="for all PLWHA [119, 120]. New regimens as short"/>
  <result pre="HIV/AIDS services exist: TB services should test for HIV (allowing" exact="treatment" post="of TB patients with antiretrovirals and cotrimoxazole preventive therapy"/>
  <result pre="test (TST) or IFN-Î³ release assay (IGRA), and initiate prompt" exact="treatment" post="of TB or LTBI in PLWHA [119, 120]. Based"/>
  <result pre="3) decrease the burden of HIV among TB patients. Moreover," exact="testing" post="for other infections in addition to HIV in TB"/>
  <result pre="SARS may be due to CD4 lymphopenia during the viral" exact="infection" post="[124], as CD4+ T-cells are crucial for TB-specific immunity"/>
  <result pre="TB patients [132], although it was unclear which the initial" exact="infection" post="was. TB and COVID-19 There may be interaction between"/>
  <result pre="separate anecdotal report, L iuet al. [133] reported an increased" exact="prevalence" post="of LTBI in patients with severe COVID-19 infection and"/>
  <result pre="an increased prevalence of LTBI in patients with severe COVID-19" exact="infection" post="and concluded that infection with M. tuberculosis may influence"/>
  <result pre="LTBI in patients with severe COVID-19 infection and concluded that" exact="infection" post="with M. tuberculosis may influence the progression and outcome"/>
  <result pre="age is a risk factor for active TB with poorer" exact="treatment" post="outcomes [1, 141], while TB symptoms are indistinguishable from"/>
  <result pre="incarcerated, although there should be equity in the availability of" exact="testing" post="and treatment. The elderly may further have technical difficulties"/>
  <result pre="impaired cough response. A poor quality respiratory sample inevitably delays" exact="diagnosis" post="and contact tracing efforts. Treatment and management of viral"/>
  <result pre="response. A poor quality respiratory sample inevitably delays diagnosis and" exact="contact tracing" post="efforts. Treatment and management of viral infections and TB"/>
  <result pre="A poor quality respiratory sample inevitably delays diagnosis and contact" exact="tracing" post="efforts. Treatment and management of viral infections and TB"/>
  <result pre="Treatment and management of viral infections and TB includes prompt" exact="isolation" post="of presumptive cases and of microbiologically confirmed cases depending"/>
  <result pre="147]. Diagnostic challenges in viral diseases and TB For prompt" exact="diagnosis" post="of viruses causing severe acute respiratory infections [148], such"/>
  <result pre="mutations and clusters using phylogenetic approaches [155, 156]. Specific antibody" exact="detection" post="remains useful for seroprevalence studies in selected populations and"/>
  <result pre="[153]. TABLE 1 Performance characteristics of diagnostic approaches to respiratory" exact="infection" post="Respiratory viruses Mycobacterium tuberculosis complex Sensitivity Specificity Time to"/>
  <result pre="uncommon viruses Sensitivity Specificity Time saving User friendly Drug susceptibility" exact="testing" post="Molecular diagnosis â€ƒManual NAAT +â€Š+â€Š+ +â€Š+â€Š+ âˆ’ âˆ’ âˆ’"/>
  <result pre="Sensitivity Specificity Time saving User friendly Drug susceptibility testing Molecular" exact="diagnosis" post="â€ƒManual NAAT +â€Š+â€Š+ +â€Š+â€Š+ âˆ’ âˆ’ âˆ’ +â€Š+â€Š+ +â€Š+"/>
  <result pre="+ âˆ’ âˆ’ + +â€Š+â€Š+ +â€Š+â€Š+ âˆ’ âˆ’ +â€Š+â€Š+ Antigen" exact="detection" post="â€ƒPOCT âˆ’ + +â€Š+â€Š+ +â€Š+ âˆ’ +Æ’ +â€Š+ +â€Š+â€Š+"/>
  <result pre="of the procedure &amp;lt;2â€…h; Â¶: metagenomics and whole-genome sequencing; +:" exact="immunofluorescence" post="microscopy on respiratory samples to detect the most common"/>
  <result pre="to monitor therapy. Diagnosis of active TB relies on direct" exact="detection" post="of M. tuberculosis, most often in respiratory specimens. Although"/>
  <result pre="potential of microbiological laboratories, producing an invaluable asset to improve" exact="diagnosis" post="against other infections including TB. At the same time,"/>
  <result pre="same time, the expertise, tools and networks developed for TB" exact="diagnosis" post="could aid the rapid implementation of molecular diagnosis of"/>
  <result pre="for TB diagnosis could aid the rapid implementation of molecular" exact="diagnosis" post="of COVID-19 and other viral infections. Tests (lateral flow"/>
  <result pre="secretions and to determine serological evidence of recent and past" exact="infection" post="and evidence of neutralising antibodies are currently being evaluated."/>
  <result pre="or treat secondary infections [84, 86, 161]. To provide active" exact="treatment" post="for SARS-CoV-2, drugs potentially inhibiting viral replication are of"/>
  <result pre="trials is necessary. Lopinavir/ritonavir (Kaletra) Lopinavir/ritonavir is a widely studied" exact="treatment" post="for COVID-19, although evidence of efficacy is still limited"/>
  <result pre="clinical response compared with standard of care [165]. For the" exact="treatment" post="of TB/HIV co-infected patients, lopinavir/ritonavir is not recommended in"/>
  <result pre="of lopinavir/ritonavir by additional ritonavir in children on rifampicin-based TB" exact="treatment" post="could be attempted as comparable drug exposure was achieved"/>
  <result pre="good quality to support the use of steroids outside the" exact="treatment" post="of TB meningitis is scarce [163]. Evidence on the"/>
  <result pre="an effective treatment, the tools to control a new viral" exact="infection" post="have remained the same as during the 1918 influenza"/>
  <result pre="designed to reduce the risk of transmission and spread of" exact="infection" post="such as increased respiratory hygiene, cough etiquette and hand"/>
  <result pre="as increased respiratory hygiene, cough etiquette and hand washing, voluntary" exact="isolation" post="of infected individuals or households as well as quarantine"/>
  <result pre="voluntary isolation of infected individuals or households as well as" exact="quarantine" post="of their contacts, followed by voluntary or mandatory physical"/>
  <result pre="as quarantine of their contacts, followed by voluntary or mandatory" exact="physical distancing" post="measures, restrictions on travel and transportation, and dissemination of"/>
  <result pre="measures, restrictions on travel and transportation, and dissemination of basic" exact="infection" post="prevention and control messages and advice to the general"/>
  <result pre="and/or transmission of infections (see the following subsection on â€œAirborne" exact="infection" post="control and workplace safetyâ€�). Containment, through early detection, investigation"/>
  <result pre="through early detection, investigation and reporting of cases, together with" exact="contact tracing" post="with self-isolation, aims at containing, preventing or delaying the"/>
  <result pre="early detection, investigation and reporting of cases, together with contact" exact="tracing" post="with self-isolation, aims at containing, preventing or delaying the"/>
  <result pre="(buffer zone) for secondary infections [186]. Delaying the spread of" exact="infection" post="can be achieved by early identification and treatment of"/>
  <result pre="spread of infection can be achieved by early identification and" exact="treatment" post="of cases, monitoring and follow-up of contacts, physical distancing"/>
  <result pre="identification and treatment of cases, monitoring and follow-up of contacts," exact="physical distancing" post="measures such as proscribing public or religious gatherings and"/>
  <result pre="showed that in the USA, cities that introduced early social" exact="isolation" post="measures experienced a significant reduction of viral spread, approximately"/>
  <result pre="not, with a consequent reduction on healthcare pressures [187]. Airborne" exact="infection" post="control and workplace safety Airborne infection control in healthcare"/>
  <result pre="healthcare pressures [187]. Airborne infection control and workplace safety Airborne" exact="infection" post="control in healthcare settings uses a hierarchy of control"/>
  <result pre="the community spread of COVID-19 during the early stages of" exact="infection" post="and from asymptomatic individuals is strongly discussed [191, 193,"/>
  <result pre="by the general population may reduce the spread of the" exact="infection" post="in the community by minimising the excretion of respiratory"/>
  <result pre="developed symptoms or who remain asymptomatic [198]. In general, all" exact="infection" post="control measures are important to prevent infections and render"/>
  <result pre="including the shortage of PCR reagents being used for COVID-19" exact="diagnosis" post="which may impact on molecular TB diagnosis. Moreover, the"/>
  <result pre="as fear can significantly hinder or delay access to TB" exact="diagnosis" post="and care. Fear, defined as an instinctive emotional reaction"/>
  <result pre="associated with healthcare such as the fear that receiving a" exact="diagnosis" post="of TB or TB treatment could affect the way"/>
  <result pre="the fear that receiving a diagnosis of TB or TB" exact="treatment" post="could affect the way they are perceived by society"/>
  <result pre="well-recognised barriers to timely access to care [214]. In addition," exact="physical distancing" post="measures imposed to reduce the transmission of COVID-19 (SARS-CoV-2)"/>
  <result pre="and limited access to public transport, police patrols, and enforced" exact="isolation" post="measures all have a potential deleterious impact on access"/>
  <result pre="measures has several limitations. First, there is substantial heterogeneity in" exact="physical distancing" post="policies and their implementation between countries. For instance, the"/>
  <result pre="There are multiple interactions at the different levels of prevention," exact="diagnosis" post="and treatment between the responses to TB and COVID-19"/>
  <result pre="multiple interactions at the different levels of prevention, diagnosis and" exact="treatment" post="between the responses to TB and COVID-19 [135, 136,"/>
  <result pre="and COVID-19 [135, 136, 216]. Similarities and differences related to" exact="infection" post="control and workplace safety have been discussed. For diagnosis,"/>
  <result pre="presence of cough, fever and other nonspecific symptoms complicates differential" exact="diagnosis" post="of TB, COVID-19 and other respiratory infections [135]. The"/>
  <result pre="of TB, COVID-19 and other respiratory infections [135]. The necessary" exact="physical distancing" post="policies are likely to negatively affect active case finding"/>
  <result pre="influenza [217, 218]. Both clinical and programmatic approaches to TB" exact="treatment" post="are also affected in high-burden countries and drug procurement"/>
  <result pre="against either TB or COVID-19. While a sustainable and effective" exact="treatment" post="programme is the key to successful control of TB,"/>
  <result pre="[222]. Triage of suspected cases and patients according to their" exact="isolation" post="and treatment needs will help to maximise the healthcare"/>
  <result pre="of suspected cases and patients according to their isolation and" exact="treatment" post="needs will help to maximise the healthcare throughput with"/>
  <result pre="the mounting patient load and avoid major breaches in nosocomial" exact="infection" post="control and total collapse of the healthcare system. Breaking"/>
  <result pre="in the absence of an effective vaccine. Controlling a respiratory" exact="infection" post="at source is often more cost-effective than targeting multiple"/>
  <result pre="limited and contradictory [195, 225]. For both diseases, early case" exact="detection" post="is important for source control, but case finding may"/>
  <result pre="is needed to contain the spread of COVID-19. Like TB," exact="contact tracing" post="may only pick up a small portion of COVID-19"/>
  <result pre="needed to contain the spread of COVID-19. Like TB, contact" exact="tracing" post="may only pick up a small portion of COVID-19"/>
  <result pre="otherwise exponential growth of the COVID-19 epidemic [193]. The current" exact="physical distancing" post="and stay-at-home measures imposed due to the COVID-19 pandemic"/>
  <result pre="pose challenges to TB programmes to provide the necessary diagnosis," exact="treatment" post="and care for the people and communities affected by"/>
  <result pre="sd 1. Large droplets increase the risk of respiratory viral" exact="infection" post="through direct transmission. 0 (0.0) 6 (16.2) 6 (16.2)"/>
  <result pre="3.7Â±1.1 12. Chloroquine and hydroxychloroquine have potential to improve the" exact="treatment" post="success rate of COVID-19 patients. RCTs are needed. 4"/>
  <result pre="10 (27.0) 9 (24.3) 6 (16.2) 3.1Â±1.3 13. Public and" exact="social distancing" post="reduce the risk of SARS-CoV-2 transmission. 0 (0.0) 0"/>
  <result pre="patients and their contacts can reduce the risk of SARS-CoV-2" exact="infection" post="by limiting the spread of droplet nuclei from isolated"/>
  <result pre="diseases are droplet-borne. The diagnostic tools range from nucleic acid" exact="detection" post="and molecular techniques to immunoassays and traditional cultures for"/>
  <result pre="were discussed, including drugs, DDIs, novel therapies, and principles of" exact="infection" post="control and workplace safety. COVID-19 and TB interactions were"/>
  <result pre="air and surface samples at a New York City feline" exact="quarantine" post="facility. Influenza Other Respir Viruses2018; 12: 613â€&quot;622. doi:10.1111/irv.1257229768714 6LeungNH,"/>
  <result pre="Med2017; 38: 1â€&quot;9. doi:10.1016/j.ccm.2016.11.01228159152 12VargaZ, FlammerAJ, SteigerP, et al.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19. Lancet2020; 395: 1417â€&quot;1418. doi:10.1016/S0140-6736(20)30937-532325026 13JainS,"/>
  <result pre="Opin Virol2013; 3: 468â€&quot;474. doi:10.1016/j.coviro.2013.05.00523806514 24KrishnamoorthyN, KhareA, OrissTB, et al.Early" exact="infection" post="with respiratory syncytial virus impairs regulatory T cell function"/>
  <result pre="et al.ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis" exact="infection" post="are initiated in the mediastinal lymph nodes. Proc Natl"/>
  <result pre="CD8+ T cells are functionally and phenotypically different between latent" exact="infection" post="and active disease. Eur J Immunol2013; 43: 1568â€&quot;1577. doi:10.1002/eji.20124326223456989"/>
  <result pre="Al DulayymiJR, et al.New synthetic lipid antigens for rapid serological" exact="diagnosis" post="of tuberculosis. PLoS One2017; 12: e0181414. doi:10.1371/journal.pone.018141428806423 49Biering-SorensenS, JensenKJ,"/>
  <result pre="759â€&quot;766. doi:10.1093/infdis/jix61229216358 50NemesE, GeldenhuysH, RozotV, et al.Prevention of M. tuberculosis" exact="infection" post="with H4:IC31 vaccine or BCG revaccination. N Engl J"/>
  <result pre="53ArtsRJW, MoorlagS, NovakovicB, et al.BCG vaccination protects against experimental viral" exact="infection" post="in humans through the induction of cytokines associated with"/>
  <result pre="doi:10.1371/journal.pone.018014328686604 55SpencerJC, GangulyR, WaldmanRHNonspecific protection of mice against influenza virus" exact="infection" post="by local or systemic immunization with Bacille Calmette-Guerin. J"/>
  <result pre="is significantly confounded by age and is unlikely to alter" exact="infection" post="or mortality rates. medRxiv 2020; preprint [10.1101/2020.04.06.20055616]. doi:10.1101/2020.04.06.20055616 60DaoudA,"/>
  <result pre="8: 17â€&quot;20. doi:10.4161/hv.8.1.1814522252002 65MeterskyML, MastertonRG, LodeH, et al.Epidemiology, microbiology, and" exact="treatment" post="considerations for bacterial pneumonia complicating influenza. Int J Infect"/>
  <result pre="Infect Dis2020; 71: 1547â€&quot;1551. doi:10.1093/cid/ciaa19832112072 89LuX, ZhangL, DuH, et al.SARS-CoV-2" exact="infection" post="in children. N Engl J Med2020; 382: 1663â€&quot;1665. doi:10.1056/NEJMc200507332187458"/>
  <result pre="WangT, et al.Diagnosis, treatment, and prevention of 2019 novel coronavirus" exact="infection" post="in children: expertsâ€™ consensus statement. World J Pediatr2020; 16:"/>
  <result pre="142: 2036â€&quot;2048. doi:10.1017/S095026881300314224331081 114RothS, WhiteheadS, ThamthitiwatS, et al.Concurrent influenza virus" exact="infection" post="and tuberculosis in patients hospitalized with respiratory illness in"/>
  <result pre="East respiratory syndrome coronavirus and pulmonary tuberculosis coinfection: implications for" exact="infection" post="control. Intervirology2017; 60: 53â€&quot;55. doi:10.1159/00047790828683463 133LiuY, BiL, ChenY, et"/>
  <result pre="doi:10.3760/cma.j.issn.0254-6450.2020.02.00332064853 139WangJT, ShengWH, FangCT, et al.Clinical manifestations, laboratory findings, and" exact="treatment" post="outcomes of SARS patients. Emerging Infect Dis2004; 10: 818â€&quot;824."/>
  <result pre="Clin Infect Dis2014; 59: 166â€&quot;174. doi:10.1093/cid/ciu28524785230 141collab: World Health OrganizationSystematic" exact="screening" post="for active tuberculosis: principles and recommendations. Geneva, WHO, 2013."/>
  <result pre="WHO, 2013. 142JamiesonDJ, HoneinMA, RasmussenSA, et al.H1N1 2009 influenza virus" exact="infection" post="during pregnancy in the USA. Lancet2009; 374: 451â€&quot;458. doi:10.1016/S0140-6736(09)61304-019643469"/>
  <result pre="Rev2006; 19: 614â€&quot;636. doi:10.1128/CMR.00005-0617041137 158MachadoD, CoutoI, ViveirosMAdvances in the molecular" exact="diagnosis" post="of tuberculosis: from probes to genomes. Infect Genet Evol2019;"/>
  <result pre="and decentralized care on linkage to care and drug-resistant tuberculosis" exact="treatment" post="outcomes in Johannesburg, South Africa. BMC Health Serv Res2018;"/>
  <result pre="doi:10.3899/jrheum.14009924788997 161collab: World Health OrganizationClinical management of severe acute respiratory" exact="infection" post="when COVID-19 is suspected: interim guidance. Geneva, WHO, 2020."/>
  <result pre="doi:10.1101/2020.03.22.20040758 170GautretP, LagierJC, ParolaP, et al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
  <result pre="31: 257â€&quot;274. doi:10.2165/00003088-199631040-000038896943 177ToniatiP, PivaS, CattaliniM, et al.Tocilizumab for the" exact="treatment" post="of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute"/>
  <result pre="53: 1900391. doi:10.1183/13993003.00391-201931023852 189collab: World Health OrganizationWHO guidelines on tuberculosis" exact="infection" post="prevention and control: 2019 update. Geneva, WHO, 2019. 190ThorneCD,"/>
  <result pre="McDiarmidMAUsing the hierarchy of control technologies to improve healthcare facility" exact="infection" post="control: lessons from severe acute respiratory syndrome. J Occup"/>
  <result pre="5: e006577. doi:10.1136/bmjopen-2014-006577 196LeungCC, ChengKK, LamTH, et al.Masking to complement" exact="social distancing" post="in saving lives in COVID-19 pandemic. Int J Tuberc"/>
  <result pre="2020. 223collab: Centers for Disease Control and PreventionGuidelines for environmental" exact="infection" post="control in health-care facilities2003www.cdc.gov/infectioncontrol/guidelines/environmental/index.htmlDate last accessed: July 7, 2020"/>
  <result pre="Cell2020; 181:271â€&quot;280. doi:10.1016/j.cell.2020.02.05232142651 230RichardsonP, GriffinI, TuckerC, et al.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory disease. Lancet2020; 395: e30â€&quot;e31. doi:10.1016/S0140-6736(20)30304-432032529"/>
  <result pre="XuS, et al.Learning from the past: possible urgent prevention and" exact="treatment" post="options for severe acute respiratory infections caused by 2019-nCoV."/>
  <result pre="2019-nCoV. Chembiochem2020; 21: 730â€&quot;738. doi:10.1002/cbic.20200004732022370 232JordanPC, StevensSK, DevalJNucleosides for the" exact="treatment" post="of respiratory RNA virus infections. Antivir Chem Chemother2018; 26:"/>
  <result pre="doi:10.1371/journal.pone.010561725144636 236AbrahamGM, MortonJB, SaravolatzLDBaloxavir: a novel antiviral agent in the" exact="treatment" post="of influenza. Clin Infect Dis2020; in press [10.1093/cid/ciaa107]. doi:10.1093/cid/ciaa107"/>
  <result pre="Biol Chem2020; 295: 4773â€&quot;4779. doi:10.1074/jbc.AC120.01305632094225 238BustiAJ, HallRG, MargolisDMAtazanavir for the" exact="treatment" post="of human immunodeficiency virus infection. Pharmacotherapy2004; 24: 1732â€&quot;1747. doi:10.1592/phco.24.17.1732.5234715585441"/>
  <result pre="of the pharmacokinetic and pharmacodynamic properties of drugs considered for" exact="testing" post="in human efficacy trials. Clin Pharmacokinet2016; 55: 907â€&quot;923. doi:10.1007/s40262-015-0364-126798032"/>
 </snippets>
</snippetsTree>
